HC Wainwright issued their Q1 2025 EPS estimates for shares of Zevra Therapeutics in a note issued to investors on Thursday, ...

Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Aligos Therapeutics in a report issued on Tuesday, March 11th. HC Wainwright analyst E.

H.C. Wainwright lowered the firm’s price target on Vigil Neuroscience (VIGL) to $14 from $17 and keeps a Buy rating on the shares ahead of ...

H.C. Wainwright lowered the firm’s price target on Cartesian Therapeutics (RNAC) to $40 from $45 and keeps a Buy rating on the shares. The firm ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

Quantum computing continues to advance rapidly, which has been helping businesses get new opportunities related to security, ...

Discover how Bit Digital's Q4 2024 results showcase a 141% revenue increase, a strategic shift to HPC with WhiteFiber, and a strong pipeline for ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at ...

U.S. stocks were higher, with the Dow Jones index gaining around 1% on Friday. Shares of Semtech Corporation SMTC rose ...

Hello, and welcome to the Bit Digital Fiscal Year 2024 earnings conference call. Good morning, good afternoon and good evening, depending on where you're joining us from. Thank you for being here.

Welcome to the Aemetis fourth-quarter and year-end 2024 earnings review conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce ...